Insulin glargine, a long-acting form of insulin, was marketed under the brand name LANTUS. Lantus is indicated for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia. The primary activity of insulin glargine is regulation of glucose metabolism. It lowers blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. The off-label use of insulin glargine is the treatment type 2 diabetes in children and the treatment of gestational diabetes.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P06213 Gene ID: 3643.0 Gene Symbol: INSR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/18585815 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | LANTUS Approved UseLANTUS is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Launch Date2000 |
|||
| Primary | LANTUS Approved UseLANTUS is indicated for once-daily subcutaneous administration at bedtime in the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia. Launch Date2000 |
| Substance Class |
Protein
Created
by
admin
on
Edited
Mon Mar 31 23:16:59 GMT 2025
by
admin
on
Mon Mar 31 23:16:59 GMT 2025
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
2ZM8CX04RZ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Related Record | Type |
|---|
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NDF-RT |
N0000175453
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
||
|
WHO-ATC |
A10AE54
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
||
|
NDF-RT |
N0000004931
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
||
|
NDF-RT |
N0000004931
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
||
|
WHO-ATC |
A10AE04
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
||
|
NDF-RT |
N0000004931
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
||
|
WHO-VATC |
QA10AE04
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000085460
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
PRIMARY | |||
|
C106526
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
PRIMARY | |||
|
DTXSID0043927
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
PRIMARY | |||
|
INSULIN GLARGINE
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
PRIMARY | |||
|
SUB08196MIG
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
PRIMARY | |||
|
2ZM8CX04RZ
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
PRIMARY | |||
|
1342059
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
PRIMARY | |||
|
2ZM8CX04RZ
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
PRIMARY | |||
|
LL-87
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
PRIMARY | |||
|
7572
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
PRIMARY | |||
|
7548
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
PRIMARY | |||
|
160337-95-1
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
PRIMARY | |||
|
274783
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
PRIMARY | RxNorm | ||
|
4901
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201497
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
PRIMARY | |||
|
m6297
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
PRIMARY | Merck Index | ||
|
118984454
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
PRIMARY | |||
|
C47564
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
PRIMARY | |||
|
DB00047
Created by
admin on Mon Mar 31 23:16:59 GMT 2025 , Edited by admin on Mon Mar 31 23:16:59 GMT 2025
|
PRIMARY |
| From | To |
|---|---|
| 1_7 | 2_7 |
| 1_19 | 2_20 |
| 2_6 | 2_11 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SUB_CONCEPT->SUBSTANCE |
|
||
|
BIOSIMILAR -> PARENT |
|
||
|
|
TARGET -> AGONIST |
|
||
|
|
SUB_CONCEPT->SUBSTANCE |
|
||
|
BIOSIMILAR -> PARENT |
|
||
|
|
SUB_CONCEPT->SUBSTANCE |
|
||
|
|
BIOSIMILAR -> PARENT |
|
||
|
SUB_CONCEPT->SUBSTANCE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
||
|
|
ACTIVE MOIETY |
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|
||||
| Molecular Formula | CHEMICAL |
|